|
1
|
Magnani G and Valgimigli M: Dual
antiplatelet therapy after drug-eluting stent implantation. Interv
Cardiol. 11:51–53. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kim JY and Yoon J: Aspirin and Clopidogrel
Resistance in Drug Eluting Stent Era. Korean Circ J. 37:135–147.
2007.
|
|
3
|
Khan SU, Singh M, Valavoor S, Khan MU,
Lone AN, Khan MZ, Khan MS, Mani P, Kapadia SR, Michos ED, et al:
Dual antiplatelet therapy after percutaneous coronary intervention
and drug-eluting stents: A systematic review and network
meta-analysis. Circulation. 142:1425–1436. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Watanabe H, Morimoto T, Natsuaki M,
Yamamoto K, Obayashi Y, Ogita M, Suwa S, Isawa T, Domei T, Yamaji
K, et al: Comparison of clopidogrel monotherapy after 1 to 2 months
of dual antiplatelet therapy with 12 months of dual antiplatelet
therapy in patients with acute coronary Syndrome: The STOPDAPT-2
ACS Randomized clinical trial. JAMA Cardiol. 7:407–417.
2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhong PY, Shang YS, Bai N, Ma Y, Niu Y and
Wang ZL: Efficacy and safety of very short-term dual antiplatelet
therapy after drug-eluting stents implantation for acute coronary
Syndrome: A systematic review and meta-analysis of Randomized
Clinical Trials. Front Cardiovasc Med. 8(660360)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Luo L, Wang S, Tang K, Yang X, Wu J, Wang
D, Xu L, Feng T, Li D, Ran J, et al: Efficacy and safety of dual
antiplatelet therapy after percutaneous coronary drug-eluting
stenting: A network meta-analysis. Medicine (Baltimore).
101(e31158)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Rangé G, Yayehd K, Belle L, Thuaire C,
Richard P, Cazaux P, Barbou F, Köning R, Chassaing S, Teiger E, et
al: Thrombotic and bleeding events after coronary stenting
according to clopidogrel and aspirin platelet reactivity: VerifyNow
French Registry (VERIFRENCHY). Arch Cardiovasc Dis. 107:225–235.
2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bouman HJ, van Werkum JW, Breet NJ, ten
Cate H, Hackeng CM and ten Berg JM: A case-control study on
platelet reactivity in patients with coronary stent thrombosis. J
Thromb Haemost. 9:909–916. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Breet NJ, van Werkum JW, Bouman HJ, Kelder
JC, Harmsze AM, Hackeng CM and ten Berg JM: High on-treatment
platelet reactivity to both aspirin and clopidogrel is associated
with the highest risk of adverse events following percutaneous
coronary intervention. Heart. 97:983–990. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Karabulut D, Kaya A, Abacı O, Karabulut U,
Turhan Çağlar FN and Arat-Özkan A: The frequency of aspirin and
clopidogrel resistance and related factors in patients undergoing
elective percutaneous coronary intervention. EJCM. 9:94–104.
2021.
|
|
11
|
Akturk IF, Caglar FN, Erturk M, Tuncer N,
Yalcın AA, Surgit O, Uzun F and Caglar IM: Hypertension as a risk
factor for aspirin and clopidogrel resistance in patients with
stable coronary artery disease. Clin Appl Thromb Hemost.
20:749–754. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang L, Lv Y, Dong J, Wang N, Zhan Z,
Zhao Y and Jiang S: Assessment of risk factors for drug resistance
of dual anti platelet therapy after PCI. Clin Appl Thromb Hemost.
28(10760296221083674)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pendyala LK, Torguson R, Loh JP, Devaney
JM, Chen F, Kitabata H, Minha S, Barbash IM, Suddath WO, Satler LF,
et al: Racial disparity with on-treatment platelet reactivity in
patients undergoing percutaneous coronary intervention. Am Heart J.
166:266–272. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Akkaif MA, Daud NAA, Sha'aban A, Ng ML,
Abdul Kader MAS, Noor DAM and Ibrahim B: The role of genetic
polymorphism and other factors on clopidogrel resistance (CR) in an
Asian Population with Coronary Heart Disease (CHD). Molecules.
26(1987)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Uzun F, Biyik I, Akturk IF, Erturk M,
Yalcin AA, Surgit O, Oner E, Pusuroglu H and Birand A: Antiplatelet
resistance and the role of associated variables in stable patients
treated with stenting. Postepy Kardiol Interwencyjnej. 11:19–25.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mărginean A, Bănescu C, Scridon A and
Dobreanu M: Anti-platelet therapy resistance-concept, mechanisms
and platelet function tests in intensive care facilities. J Crit
Care Med (Targu Mures). 2:6–15. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Garabedian T and Alam S: High residual
platelet reactivity on clopidogrel: its significance and
therapeutic challenges overcoming clopidogrel resistance.
Cardiovasc Diagn Ther. 3:23–37. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gurbel PA, Bliden KP, Hiatt BL and
O'Connor CM: Clopidogrel for coronary stenting: Response
variability, drug resistance, and the effect of pretreatment
platelet reactivity. Circulation. 107:2908–2913. 2003.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Stone GW, Witzenbichler B, Weisz G,
Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL,
Mazzaferri E, et al: Platelet reactivity and clinical outcomes
after coronary artery implantation of drug-eluting stents
(ADAPT-DES): A prospective multicentre registry study. Lancet.
382:614–623. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhang Y, Fan D, Qiao S and Hu H: Verifynow
P2Y12 PRU-Guided modification of clopidogrel for
prevention of recurrent ischemic stroke: A real-world prospective
cohort study. Neurol Ther. 11:1749–1766. 2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Prabhakaran S, Wells KR, Lee VH, Flaherty
CA and Lopes DK: Prevalence and risk factors for aspirin and
clopidogrel resistance in cerebrovascular stenting. AJNR Am J
Neuroradiol. 29:281–285. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Godino C, Mendolicchio L, Figini F, Latib
A, Sharp AS, Cosgrave J, Calori G, Cera M, Chieffo A, Castelli A,
et al: Comparison of VerifyNow-P2Y12 test and Flow Cytometry for
monitoring individual platelet response to clopidogrel. What is the
cut-off value for identifying patients who are low responders to
clopidogrel therapy? Thromb J. 7(4)2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kim H, Lee HK, Han K and Jeon HK:
Prevalence and risk factors for aspirin and clopidogrel resistance
in patients with coronary artery disease or ischemic
cerebrovascular disease. Ann Clin Lab Sci. 39:289–294.
2009.PubMed/NCBI
|
|
24
|
Grinstein J and Cannon CP: Aspirin
resistance: Current status and role of tailored therapy. Clin
Cardiol. 35:673–681. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Virk HUH, Escobar J, Rodriguez M, Bates
ER, Khalid U, Jneid H, Birnbaum Y, Levine GN, Smith SC Jr and
Krittanawong C: Dual antiplatelet therapy: A concise review for
clinicians. Life (Basel). 13(1580)2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ebrahimi P, Farhadi Z, Behzadifar M,
Shabaninejad H, Abolghasem Gorji H, Taheri Mirghaed M, Salemi M,
Amin K, Mohammadibakhsh R, Bragazzi NL and Sohrabi R: Prevalence
rate of laboratory defined aspirin resistance in cardiovascular
disease patients: A systematic review and meta-analysis. Caspian J
Intern Med. 11:124–134. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Infeld M, Friede KA, San TR, Knickerbocker
HJ, Ginsburg GS, Ortel TL and Voora D: Platelet reactivity in
response to aspirin and ticagrelor in African-Americans and
European-Americans. J Thromb Thrombolysis. 51:249–259.
2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chadha DS, Sumana B, Karthikeyan G,
Jayaprasad V and Arun SS: Prevalence of aspirin resistance in
Asian-Indian patients with stable coronary artery disease. Catheter
Cardiovasc Interv. 88:E126–E131. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hasan MS, Basri HB, Hin LP and Stanslas J:
Genetic polymorphisms and drug interactions leading to clopidogrel
resistance: Why the Asian population requires special attention.
Int J Neurosci. 123:143–154. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chung J, Han JK, Kim YJ, Kim CJ, Ahn Y,
Chan Cho M, Chae SC, Chae IH, Chae JK, Seong IW, et al: Benefit of
Vasodilating β-Blockers in patients with acute myocardial
infarction after percutaneous coronary intervention: nationwide
multicenter cohort study. J Am Heart Assoc.
6(e007063)2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Bonten TN, Plaizier CE, Snoep JJ, Stijnen
T, Dekkers OM and van der Bom JG: Effect of β-blockers on platelet
aggregation: A systematic review and meta-analysis. Br J Clin
Pharmacol. 78:940–949. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhang S, Wu Y, Lv C, Liu H, Wang Y, Dong
L, Liu Y, Wang S, Jia J and Yin T: β1-blockers in the reduction of
bleeding risk in patients prescribed with potent dual antiplatelet
therapy after acute coronary syndrome or percutaneous coronary
intervention. Hellenic J Cardiol: Oct 12, 2023 (Epub ahead of
print).
|
|
33
|
Su JF, Hu XH and Li CY: Risk factors for
clopidogrel resistance in patients with ischemic cerebral
infarction and the correlation with ABCB1 gene rs1045642
polymorphism. Exp Ther Med. 9:267–271. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Niijima S, Ohmori T and Kario K:
Differential impact of diabetes mellitus on antiplatelet effects of
prasugrel and clopidogrel. Thromb J. 16(5)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sweeny JM, Angiolillo DJ, Franchi F,
Rollini F, Waksman R, Raveendran G, Dangas G, Khan ND, Carlson GF,
Zhao Y, et al: Impact of diabetes mellitus on the pharmacodynamic
effects of ticagrelor versus clopidogrel in troponin-negative acute
coronary Syndrome patients undergoing ad hoc percutaneous coronary
intervention. J Am Heart Assoc. 6(e005650)2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kakouros N, Kickler TS, Laws KM and Rade
JJ: Hematocrit alters VerifyNow P2Y12 assay results independently
of intrinsic platelet reactivity and clopidogrel responsiveness. J
Thromb Haemost. 11:1814–1822. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kim YG, Suh JW, Park JJ, Oh IY, Yoon CH,
Cho YS, Youn TJ, Chae IH and Choi DJ: Different influences of
hematocrit on the results of two Point-Of-Care platelet function
tests, the VerifyNow assay and multiple electrode platelet
aggregometry. PLoS One. 9(e114053)2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kim YG, Suh JW, Sibbing D, Kastrati A, Ko
YG, Jang Y, Cho YS, Youn TJ, Chae IH, Choi DJ and Kim HS: A
laboratory association between hemoglobin and VerifyNow P2Y12
reaction unit: A systematic review and meta-analysis. Am Heart J.
188:53–64. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Janssen PW, Bergmeijer TO, Godschalk TC,
Le TT, Breet NJ, Kelder JC, Hackeng CM and Ten Berg JM: The effect
of correcting VerifyNow P2Y12 assay results for hematocrit in
patients undergoing percutaneous coronary interventions. J Thromb
Haemost. 15:618–623. 2017.PubMed/NCBI View Article : Google Scholar
|
